By Kim Dixon
WASHINGTON (Reuters) - Senator Chuck Schumer said on Wednesday that the head of the Food and Drug Administration had approached him about a plan to speed generic versions of pricey biotech drugs to the market.
FDA Commissioner Andrew von Eschenbach "came to my office last night and said: 'Let's work together on generic biologics.'" Schumer, a Democrat from New York, told the Reuters Regulation Summit.
Based on initial discussions, "we're not that far apart," he said.
The meeting came days after the Republican administration of President George W. Bush surprised many by calling for legislation enabling the FDA to approve generic versions of biotech medicines, also known as biologics, which are made from proteins from living cells.
Copycat versions could provide big cost savings for insurers and patients, some of whom pay thousands of dollars for branded biotech drugs, which are typically injected because they involve large proteins that are destroyed by the stomach.
The FDA was not available for comment.
Schumer, a co-sponsor of a bill in the U.S. Senate last year, said he might support the administration's call for industry user fees to help pay for the program.
He said the commissioner stopped by unannounced. "He came to me," Schumer said. "That really says something." Continued...
© Thomson Reuters 2008. All rights reserved.
| Japan Investment | Jul 01 - 2, 2008 | Country Summits |
| Global Real Estate | Jun 23 - 25, 2008 | Real Estate |
| Consumer and Retail | Jun 16 - 18, 2008 | Consumer Retail |
| Investment Outlook | Jun 09 - 12, 2008 | Financial Services / Exchanges |
| Global Energy | Jun 01 - 5, 2008 | Energy |
